The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.

In patients with chronic kidney disease, the use of an implantable cardioverter defibrillator was associated with an increased risk of heart failure and any-cause hospitalizations but not all-cause ...

The implantable cardioverter-defibrillator (ICD) is a battery-operated device that is inserted under the skin of the patient to assess and monitor the user’s heart rate. ICDs are connected to heart by ...

LONDON--(BUSINESS WIRE)--Technavio’s global implantable cardioverter defibrillators (ICD) market research report forecasts the market to grow at a CAGR of almost 2% during the forecast period. The ...

A prospective study evaluating the functionality and ease of use of the Medtronic CareLink ® Network, "CareLink," was conducted at ten investigational sites. This internet-based remote monitoring ...

AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, ...

New System Builds On Sprint Quattro® Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders MINNEAPOLIS – Medtronic, Inc. today announced the U.S.

Dr. Morton M. Mower, a pioneering cardiologist and former Sinai Hospital staff member who was co-inventor of the automatic implantable cardioverter defibrillator, died of cancer Monday at Porter ...